CTMX

2.0300.98%
SA

Sean A. McCarthy

Chairman & CEO

Dr. Sean A. McCarthy, D.Phil., served as an Independent Director at OncoResponse, Inc. since August 2021 until October 2025. He has been the Chief Executive Officer of CytomX Therapeutics, Inc. since August 2011 and has been its Chairman since January 01, 2019. Dr. McCarthy served as President of CytomX Therapeutics, Inc. since August 2011 until February 07, 2022. Dr. McCarthy joined CytomX in 2010 as Chief Business Officer. Dr. McCarthy served as a Senior Principal and was a Transactional Partner at Pappas Ventures and helped drive investments in therapeutic from April 2006 to December 2010, medical device and molecular diagnostic companies, including new company formation. Dr. McCarthy joined Pappas Ventures in August 2006. Dr. McCarthy served as the Vice President of Business Development of SGX Pharmaceuticals Inc., (formerly, Structural Genomix Inc.). Prior to Pappas, he drove a strategic reorganization of SGX Pharmaceuticals from a platform model to product-focused oncology company and served in multiple roles at Millennium Pharmaceuticals. He served as a Manager of Drug Discovery Programs and an Associate Director of Program Management at Millennium Pharmaceuticals, Inc. Prior to joining SGX, Dr. McCarthy served as a Senior Scientist and Program Director at Millennium Pharmaceuticals, where he managed biotherapeutic assets for it, including an alliance with Eli Lilly and Co. At Millennium, Dr. McCarthy was responsible for research into gene discovery and for management of several drug discovery programs. Prior to joining the Program Management group at Millennium, he managed an interdisciplinary team of scientists that developed novel genomic techniques for the identification of therapeutic proteins in the context of a major alliance with Eli Lilly. He serves as a Director of CytomX Therapeutics, Inc. Dr. McCarthy serves as a Board Observer of Optherion, Inc. He served as the Board Observer of LEAD Therapeutics, Inc. and TYRX, Inc. He served as a Board Observer of TyRx Pharma Inc. since 2008. Dr. McCarthy served as a Board Observer at Afferent Pharmaceuticals, Inc. since 2008. He served as a Director of CoLucid Pharmaceuticals Inc. He served as a Director of Genstruct Inc. (now Selventa, Inc.). Dr. McCarthy has extensive experience in the biotechnology industry having served in roles in R&D, business development, finance and general management. Dr. McCarthy is the author of 17 peer reviewed scientific publications and an inventor on six issued patents and 23 filed patent applications. Dr. McCarthy was Post-doctoral Research Fellow at DNAX Research Institute, where he analyzed oncogene-related gene expression. Dr. McCarthy received his Bachelor of Science degree in biochemistry and pharmacology at King’s College, University of London. He also received an MBA from the Rady School of Management at UCSD and a D. Phil. in cancer biology from St. John’s College, University of Oxford.

Positions